CLEVELAND, Oct. 7, 2016 /PRNewswire/ -- GenomOncology today announced the recent extension of the GO Clinical Workbench™ to support Hematologic cancer testing and decision support.
Molecular diagnostic laboratories across the country have used GenomOncology's workbench for their solid tumor testing needs for over two years. GenomOncology's clients have recently begun to validate and launch Hematologic malignancy focused panels. With new guidelines and content about Hematologic malignancies becoming available, GenomOncology utilized the GO Clinical Workbench and its Knowledge Management System (KMS) to enable accurate reporting of advanced molecular testing. To enable the vision of molecular pathologists and to meet the needs of clinicians, new features and workflows were developed to increase flexibility, while maintaining CLIA/CAP guidelines.
Hematologic malignancies are highly variable, and individual patients will likely have different treatment needs and responses to these treatments. This complexity creates a need for incorporating results from many laboratory tests and intelligently integrating these results to generate clinical recommendations. For example, the GO Clinical Workbench can parse ISCN nomenclature from cytogenetic tests, and use these findings with the mutational status of variants in FISH and NGS results to match prognostic and/or therapeutic assertions. This workflow along with other efficiencies such as custom gene panels for NGS or FISH, the ability to modify the gene list by reflex and user-defined comment templates helps optimize clinical reporting. In addition, the workflow allows labs to track individual patient's disease over time, and easily review changes in variant allele frequency based on therapeutic intervention.
GenomOncology has worked with clients such as: Medical College of Wisconsin, Pathline – Emerge, The Queen's Medical Center, UCLA Health and several others to bring this type of testing to their respective clinicians.
GenomOncology's GO Clinical Workbench for analysis and reporting is the flagship product within the GO Precision Medicine Portfolio, a suite of tools designed to help healthcare institutions implement precision oncology. The tools can be installed behind the institutions' firewall and are configured to each laboratory's specific needs.
"The laboratory testing landscape is dynamic. As the needs of the Clinical Laboratory, and the physicians that depend on them change, we will enable our partners to adapt, differentiate, and improve patient care," added Manuel Glynias, President and CEO of GenomOncology
About GenomOncology: GenomOncology is a healthcare technology company enabling precision medicine by transforming genomic data into actionable information.